The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 13, 2018

Filed:

Mar. 23, 2015
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Helen Mitchell, Richboro, PA (US);

Mark E. Fraley, North Wales, PA (US);

Andrew J. Cooke, West Point, PA (US);

Craig A. Stump, West Point, PA (US);

Xu-Fang Zhang, Dresher, PA (US);

Casey C. McComas, Phoenixville, PA (US);

Kathy Schirripa, Quakerstown, PA (US);

Melody McWherter, Boyertown, PA (US);

Ping Liu, Westfield, NJ (US);

Dann Parker, Cranford, NJ (US);

Chun Sing Li, Shanghai, CN;

Qinghua Mao, Shanghai, CN;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); C07D 487/04 (2006.01); C07D 277/46 (2006.01); C07D 231/40 (2006.01); C07D 417/12 (2006.01); C07D 401/04 (2006.01); C07D 417/14 (2006.01); C07D 403/14 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); C07D 231/40 (2013.01); C07D 277/46 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01);
Abstract

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.


Find Patent Forward Citations

Loading…